RSS
|
Login
|
Register
HOME
SPECIALTY
Hematology-Oncology
Long Term Care
Nurse Practitioners
OB/GYN
Pharmacists
Physician Assistants
Primary Care Physicians
Residents
Urologists
THERAPEUTIC CATEGORIES
BRAND
GENERIC
COMPARE
NEWS
Drug News
Drugs in the Pipeline
Drug Safety Alerts and Recalls
New Drug Products
Polls & Surveys
Newsletters
News from Haymarket Journals
RESOURCES
Alerts (Sponsored)
Clinical Charts
Common Medical Abbreviations
Company
Drug Monograph Format
FDA Orange Book
Pharmacology Notes
Professional Associations
Video
Blogs
MPR Publications
Customer Service
Online Banner Ad Specs
Subscribe
DOWNLOAD
CME
JOBS
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Home
>
Therapeutic Categories
>
Central Nervous System
> Mood disorders
Central Nervous System
»
Mood disorders
Select All |
Compare
|
Add to Clipboard
|
View Clipboard
Name
Compare
ABILIFY
compare
ABILIFY DISCMELT
compare
ABILIFY INJECTION
compare
ABILIFY ORAL SOLUTION
compare
Amitriptyline
compare
APLENZIN
compare
CELEXA
compare
CELEXA ORAL SOLUTION
compare
CYMBALTA
compare
DEPAKOTE
compare
DEPAKOTE ER
compare
EFFEXOR
compare
EFFEXOR XR
compare
EMSAM
compare
EQUETRO
compare
ESKALITH
compare
ESKALITH CR
compare
GEODON
compare
LAMICTAL
compare
LAMICTAL CHEWABLE DISPERSIBLE TABS
compare
LAMICTAL ODT
compare
LEXAPRO
compare
LEXAPRO ORAL SOLUTION
compare
Lithium carbonate capsules
compare
Lithium carbonate tablets
compare
Lithium oral solution
compare
LITHOBID
compare
MARPLAN
compare
NARDIL
compare
Nefazodone
compare
NORPRAMIN
compare
PAMELOR
compare
PAMELOR ORAL SOLUTION
compare
PARNATE
compare
PAXIL
compare
PAXIL CR
compare
PAXIL SUSPENSION
compare
PRISTIQ
compare
PROZAC
compare
PROZAC ORAL SOLUTION
compare
PROZAC WEEKLY
compare
REMERON
compare
REMERON SOLTAB
compare
RISPERDAL CONSTA
compare
RISPERDAL M-TABS
compare
RISPERDAL ORAL SOLUTION
compare
RISPERDAL TABLETS
compare
SAPHRIS
compare
SARAFEM CAPSULES
compare
SARAFEM TABLETS
compare
SEROQUEL
compare
SEROQUEL XR
compare
SINEQUAN
compare
SINEQUAN CONCENTRATE
compare
STAVZOR
compare
SURMONTIL
compare
SYMBYAX 12mg/25mg
compare
SYMBYAX 12mg/50mg
compare
SYMBYAX 3mg/25mg
compare
SYMBYAX 6mg/25mg
compare
SYMBYAX 6mg/50mg
compare
TOFRANIL
compare
TOFRANIL-PM
compare
Trazodone
compare
VIVACTIL
compare
WELLBUTRIN
compare
WELLBUTRIN SR
compare
WELLBUTRIN XL
compare
YAZ
compare
ZOLOFT
compare
ZOLOFT ORAL CONCENTRATE
compare
ZYPREXA
compare
ZYPREXA INTRAMUSCULAR
compare
ZYPREXA ZYDIS
compare
Most Popular
Most Emailed
Most Recent
FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
Pediaderm HC Complete Kit available for atopic dermatitis
Trelstar 22.5mg approved for palliative treatment of prostate cancer
New Product: SAPHRIS
®
(asenapine) Sublingual Tablets
Botox approved for upper limb spasticity
Generic timolol maleate ophthalmic gel forming solution available
FDA warns of intravascular hemolysis risk with WinRho SDF
FDA accepts NDA for lurasidone, a treatment for schizophrenia
Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
FDA warns of reduced Plavix efficacy in poor metabolizers
FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
Recommended Adult Immunization Schedule
Prevnar 13 pneumococcal disease vaccine approved
Xiaflex available for Dupuytren's contracture
Hizentra approved for primary immunodeficiency
Kapidex to be marketed under new trade name Dexilant
Ampyra available for multiple sclerosis patients
FDA grants priority review to Tasigna for newly diagnosed chronic myeloid leukemia
FDA accepts NDA for JZP-6, a treatment for fibromyalgia
Rituxan approved for chronic lymphocytic leukemia
Bowel Cleansers
Neosalus Cream available for dermatitis
FDA warns of reduced Plavix efficacy in poor metabolizers
Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
Trelstar 22.5mg approved for palliative treatment of prostate cancer
FDA accepts NDA for lurasidone, a treatment for schizophrenia
FDA warns of intravascular hemolysis risk with WinRho SDF
Botox approved for upper limb spasticity
New Product: SAPHRIS
®
(asenapine) Sublingual Tablets
Sponsored Links